# Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid Leukemia

> **NCT05445765** · PHASE1 · UNKNOWN · sponsor: **iCell Gene Therapeutics** · enrollment: 10 (estimated)

## Conditions studied

- Relapsed and/or Refractory Acute Myeloid Leukemia
- High Risk Hematologic Malignancies

## Interventions

- **BIOLOGICAL:** anti-CD33 CAR T cells

## Key facts

- **NCT ID:** NCT05445765
- **Lead sponsor:** iCell Gene Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07-01
- **Primary completion:** 2024-06-30
- **Final completion:** 2024-06-30
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2022-07-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05445765

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05445765, "Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05445765. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*